Abivax S.A 6-K, filed Jun 11, 2025
Abivax S.A. (ABVX)
6-K
2025-06-11
For: 2025-06-11
View Original
Added on
April 04, 2026
About this 6-K
Abivax S.A filed this 6-K on June 11, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2025
Commission File Number: 001-41842
Abivax SA
(Translation of registrant’s name into English)
7-11 boulevard Haussmann
75009 Paris, France
+33 (0) 1 53 83 08 41
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Abivax SA (the “Company”) held its ordinary and extraordinary general meeting of shareholders on June 6, 2025. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:
| Number of shares with voting rights | 63,436,477 | |||||||
| Total number of votes | 71,137,858 | |||||||
| Number of shareholders present, represented or voting by post | 84 | |||||||
| Number of shares present, represented or voting by post | 51,680,090 | |||||||
| Number of votes present, represented or voting by post | 58,287,655 | |||||||
| Participation rate | 81.47 | % | ||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
| Ordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
| 1. | Approval of the Company's financial statements for the financial year ended 31 December 2024. | 51,881,638 | 99.99 | % | 3,001 | 0.01 | % | 6,403,016 | — | % | |||||||||||||||||||||||||||||||
| 2. | Approval of the Company's consolidated financial statements for the financial year ended 31 December 2024. | 51,881,638 | 99.99 | % | 3,001 | 0.01 | % | 6,403,016 | — | % | |||||||||||||||||||||||||||||||
| 3. | Allocation of the income for the financial year ended 31 December 2024. | 51,881,638 | 99.99 | % | 3,001 | 0.01 | % | 6,403,016 | — | % | |||||||||||||||||||||||||||||||
| 4. | Approval of the agreements referred to Articles L. 225-38 et seq. of the French Commercial Code (Code de commerce). | 44,777,754 | 86.30 | % | 7,107,559 | 13.70 | % | 6,402,342 | — | % | |||||||||||||||||||||||||||||||
| 5. | Ratification of the cooptation of a Director (Sylvie Grégoire). | 45,279,823 | 87.27 | % | 6,605,516 | 12.73 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
| 6. | Ratification of the cooptation of a Director (Dominik Höchli). | 45,279,823 | 87.27 | % | 6,605,516 | 12.73 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
| 7. | Renewal of a Director's term of office (Corinna zur Bonsen-Thomas). | 45,279,823 | 87.27 | % | 6,605,516 | 12.73 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
| 8. | Renewal of a Director's term of office (Marc de Garidel). | 51,708,730 | 99.66 | % | 176,609 | 0.34 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
| 9. | Renewal of a Director's term of office (Camilla Soenderby). | 45,134,823 | 86.99 | % | 6,750,516 | 13.01 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
10. | Renewal of a Director's term of office (Dominik Höchli). | 45,134,823 | 86.99 | % | 6,750,516 | 13.01 | % | 6,402,316 | — | % | |||||||||||||||||||||||||||||||
11. | Renewal of the office of the Statutory Auditor (PricewaterhouseCoopers Audit). | 51,881,758 | 99.99 | % | 3,702 | 0.01 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
| Ordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
12. | Approval of the compensation items mentioned in Article L. 22-10-9 I of the French Commercial Code, pursuant to Article L. 22-10-34 of the French Commercial Code. | 45,077,059 | 86.88 | % | 6,808,954 | 13.12 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
13. | Approval of the compensation items paid during, or allocated for, the financial year 2024 to Mr. Marc de Garidel as Chair of the Board of Directors by interim and Chief Executive Officer. | 44,931,939 | 86.60 | % | 6,954,074 | 13.40 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
14. | Approval of the compensation items paid during, or allocated for, the financial year 2024 to Ms. Sylvie Grégoire as Chair of the Board of Directors. | 44,922,513 | 86.58 | % | 6,963,500 | 13.42 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
15. | Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code. | 45,077,059 | 86.88 | % | 6,808,954 | 13.12 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
16. | Approval of the compensation policy applicable to the Chair of the Board of Directors. | 44,923,450 | 86.58 | % | 6,962,563 | 13.42 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
17. | Approval of the compensation policy applicable to the Chief Executive Officer. | 44,778,450 | 86.30 | % | 7,107,563 | 13.70 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
18. | Approval of the compensation policy applicable to the Board members. | 51,378,574 | 99.02 | % | 507,439 | 0.98 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
19. | Authorization to be granted to the Board to purchase the Company's own shares. | 45,511,293 | 87.71 | % | 6,374,720 | 12.29 | % | 6,401,642 | — | % | |||||||||||||||||||||||||||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
| Extraordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
20. | Authorization to the Board of Directors to reduce share capital by cancelling treasury shares. | 51,646,018 | 99.54 | % | 239,442 | 0.46 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
21. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares, equity securities giving access to other equity securities or giving the right to the allocation of debt securities and/or securities giving access to equity securities, maintaining preferential subscription rights. | 44,824,370 | 86.39 | % | 7,061,090 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
22. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares, equity securities giving access to other equity securities or giving the right to the allocation of debt securities and/or securities giving access to equity securities, with cancellation of the preferential subscription rights by way of an offer to the public, and with the ability to confer a right of priority. | 44,824,608 | 86.39 | % | 7,060,852 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
23. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares, equity securities giving access to other equity securities or giving the right to the allocation of debt securities and/or securities giving access to equity securities, with cancellation of the preferential subscription rights in favor of a specific category of persons. | 44,823,907 | 86.39 | % | 7,061,553 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
24. | Delegation of authority to the Board of Directors to carry out a capital increase, within the limit of 30% of the share capital per year, by issuing shares, equity securities conferring access to other equity securities or conferring the right to an allotment of debt securities and/or securities conferring access to equity securities, with cancellation of the preferential subscription rights by way of a public offer to qualified investors or a restricted group of investors, within the meaning of Article L. 411-2, paragraph 1°, of the French Monetary and Financial Code (Code monétaire et financier). | 44,824,608 | 86.39 | % | 7,060,852 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
| Extraordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
25. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares, equity securities conferring access to other equity securities or conferring the right to an allotment of debt securities and/or securities conferring access to equity securities, with cancellation of the preferential subscription rights in favor of certain categories of investors within the framework of an equity financing agreement in the United States stock market known as an “At-The-Market” or “ATM Program”. | 44,824,608 | 86.39 | % | 7,060,852 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
26. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares, equity securities giving access to other equity securities or giving the right to the allocation of debt securities and/or securities giving access to equity securities, with cancellation of the preferential subscription rights in favor of designated beneficiaries. | 44,823,907 | 86.39 | % | 7,061,553 | 13.61 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
27. | Delegation of authority to the Board of Directors to increase the number of shares to be issued in the event of a capital increase with or without preferential subscription rights. | 44,978,453 | 86.69 | % | 6,907,007 | 13.31 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
28. | Delegation of authority to the Board of Directors to increase capital by capitalizing premiums, reserves, profits or other items. | 51,728,033 | 99.70 | % | 157,427 | 0.30 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
29. | Delegation of authority to the Board of Directors to issue shares and securities leading to a capital increase in consideration of non-cash contributions. | 44,978,676 | 86.69 | % | 6,905,963 | 13.31 | % | 6,403,016 | — | % | |||||||||||||||||||||||||||||||
30. | Delegation of authority to the Board of Directors to issue shares and securities entailing a capital increase in the event of a public exchange offer initiated by the Company. | 44,824,130 | 86.39 | % | 7,060,630 | 13.61 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
31. | Setting of the overall limits on the amount of the issues carried out pursuant to the delegations granted. | 51,133,700 | 98.55 | % | 750,939 | 1.45 | % | 6,403,016 | — | % | |||||||||||||||||||||||||||||||
32. | Authorization to the Board of Directors to grant share subscription and/or purchase options ("Options"), with cancellation of the shareholders' preferential subscription rights in favor of a specific category of persons. | 44,777,291 | 86.30 | % | 7,108,022 | 13.70 | % | 6,402,342 | — | % | |||||||||||||||||||||||||||||||
33. | Delegation of authority to the Board of Directors to issue and allot ordinary share warrants ("Warrants"), with cancellation of the shareholders’ preferential subscription rights in favor of a specific category of persons. | 44,777,291 | 86.30 | % | 7,108,022 | 13.70 | % | 6,402,342 | — | % | |||||||||||||||||||||||||||||||
34. | Authorization to the Board of Directors to allot free shares, whether existing or to be issued ("Free Shares"), with cancellation of the shareholders' preferential subscription rights in favor of a specific category of persons. | 44,777,291 | 86.30 | % | 7,108,022 | 13.70 | % | 6,402,342 | — | % | |||||||||||||||||||||||||||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
| Extraordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
35. | Setting of the overall limits on the amount of the issues carried out pursuant to the authorizations to grant Options and Free Shares and the delegations of authority in order to issue Warrants. | 51,877,292 | 99.99 | % | 7,468 | 0.01 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
36. | Delegation of authority to the Board of Directors to carry out a capital increase by issuing shares or securities conferring access to the Company's capital restricted to members of a company savings plan, with cancellation of the shareholders’ preferential subscription rights in favor thereof. | 35,124,435 | 67.70 | % | 16,760,775 | 32.30 | % | 6,402,445 | — | % | |||||||||||||||||||||||||||||||
37. | Modification of the corporate purpose of the Company and correlative amendments to Article 4 of the Company's bylaws (Corporate Purpose). | 51,881,758 | 99.99 | % | 3,702 | 0.01 | % | 6,402,195 | — | % | |||||||||||||||||||||||||||||||
38. | Deletion of Article 6.1 of the Company’s bylaws (Contributions - capital formation). | 51,881,759 | 99.99 | % | 3,001 | 0.01 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
39. | Amendments to Article 15.2 of the Company's bylaws (Meetings of the Board of Directors) concerning the use of a means of meetings of the Board of Directors. | 51,881,759 | 99.99 | % | 3,001 | 0.01 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
40. | Amendments to Articles 15.3 (Quorum and Majority) and 17.1 (General Management) of the Company's bylaws concerning the quorum and majority of the Board of Directors’ meetings. | 51,881,759 | 99.99 | % | 3,001 | 0.01 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
41. | Amendments to Article 15.5 of the Company's bylaws (Written consultation) concerning the written consultation of the members of the Board of Directors. | 51,881,759 | 99.99 | % | 3,001 | 0.01 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
42. | Amendments to Article 16.1 of the Company's bylaws (Powers of the Board of Directors) concerning the changes of the bylaws. | 46,477,129 | 89.58 | % | 5,407,631 | 10.42 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
| For | Against | Abstain | |||||||||||||||||||||||||||||||||||||||
Ordinary General Shareholders’ Meeting | Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||||||||||||||
43. | Powers for formalities. | 51,715,211 | 99.67 | % | 169,549 | 0.33 | % | 6,402,895 | — | % | |||||||||||||||||||||||||||||||
Press Release
On June 11, 2025, the Company published a press release entitled “Abivax releases the results of its June 6, 2025 Annual General Meeting.” A copy of the press release is filed as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.
Incorporation by Reference
This Report on Form 6-K, including Exhibit 99.1 shall be deemed to be incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-283336) and Form S-8 (File No. 333-286069) and to be part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed.
Exhibit Index | |||||
Exhibit 99.1 | |||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Abivax SA (Registrant) | ||||||||
Date: June 11, 2025 | /s/ Marc de Garidel | |||||||
| Chief Executive Officer | ||||||||
Exhibit 99.1
Abivax Announces Results of its June 6, 2025 Annual General Meeting
PARIS, France – June 11, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the “General Meeting”), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax (“Board”).
The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.
The shareholders have also ratified the appointment of Sylvie Grégoire as Chairman and the appointment of Dominik Höchli, MD as a Board member.
Details of the vote results are available on the Company’s website (www.abivax.com).
*****
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.
Contact:
Abivax Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878